Tom Donaldson, President, announced that Signet executed an Option to license all rights to medical non-invasive system to detect melanoma skin cancer using a vapor analysis system. The technology was developed by a University of Florida team led by Dr. Nikolaus Gravenstein, professor of anesthesiology, as well as a professor of neurosurgery and professor of periodontology. The breakthrough operates in real-time eliminating the time delay in diagnosis. The recently filed patent is also globally protected (PCT).
“It’s exciting to avail this technology to the medical industry. It will be profitable to Signet shareholders. As a sufferer of this disease, I have experienced many biopsies. The current diagnostic method takes up to ten days for results. Our technology is instantaneous; no stress waiting to find out if you have melanoma